Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer

BACKGROUND: BRAF V600E mutations are associated with aggressive biology and limited response to standard chemotherapy, especially during second-line and beyond therapies. BRAF V600E mutant and wild-type colorectal cancers (CRCs) differ in their expression profiles, and preclinical evidence suggests...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuishi, Toshiki, Taniguchi, Hiroya, Kotani, Daisuke, Bando, Hideaki, Komatsu, Yoshito, Shinozaki, Eiji, Nakajima, Takako Eguchi, Satoh, Taroh, Nishina, Tomohiro, Esaki, Taito, Wakabayashi, Masashi, Nomura, Shogo, Takahashi, Koji, Ono, Hiromi, Hirano, Nami, Fujishiro, Noriko, Fuse, Nozomu, Sato, Akihiro, Ohtsu, Atsushi, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863665/
https://www.ncbi.nlm.nih.gov/pubmed/31798981
http://dx.doi.org/10.1136/esmoopen-2019-000590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863665/
https://www.ncbi.nlm.nih.gov/pubmed/31798981
http://dx.doi.org/10.1136/esmoopen-2019-000590

Ejemplares similares